<DOC>
	<DOCNO>NCT00409292</DOCNO>
	<brief_summary>The purpose research study investigate RAD001 effective treatment pancreatic cancer spread respond treatment . Experiments show RAD001 prevent cell multiply . RAD002 also test laboratory experiment imitate cancer condition result promise .</brief_summary>
	<brief_title>RAD001 Previously Treated Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>- Participants take part research study give study medication-dosing calendar treatment cycle . Each cycle last four week take study drug , RAD001 , orally every day . - Participants come clinic every week time enrollment . At clinic visit blood work take monitor participant health physical exam perform . CT scan repeat every 2 month assess tumor . - Participants remain study long continue benefit study medication .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Pathologic confirmation pancreatic adenocarcinoma 18 year age old At least one measurable site disease accord RECIST criterion previously irradiate . If patient previous radiation marker lesion ( ) , must evidence progression since radiation . Treated gemcitabinebased chemotherapy document tumor progression gemcitabine intolerance gemcitabine . Prior treatment 1 prior chemotherapy regimen metastatic disease . Minimum two week since major surgery , completion radiation , completion prior systemic anticancer therapy . ECOG performance status 01 . Life expectancy great 12 week . Adequate bone marrow liver function . Must able swallow tablet . Prior treatment investigational drug within precede 4 week . Prior treatment inhibitor mTOR Chronic treatment systemic steroid another immunosuppressive agent More one prior chemotherapy treatment metastatic disease Uncontrolled brain leptomeningeal metastasis , include patient continue require glucocorticoid brain leptomeningeal metastasis . Other malignancy within past 3 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin Patients chronic renal insufficiency Other concurrent severe and/or uncontrolled medical disease could compromise participation study . Known history HIV seropositivity Impairment gastrointestinal function gastrointestinal disease significantly alter absorption RAD001 . Active , bleed diathesis oral vitamin K antagonist medication Women pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>RAD001</keyword>
	<keyword>metastatic pancreatic cancer</keyword>
</DOC>